Abstract
Non-alcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and is more prevalent in patients with type 2 diabetes mellitus (T2DM). Incretin-based antidiabetic agents (glucagonlike peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors) are used in the treatment of T2DM but it is unclear whether they may also play a role in the management of NAFLD. We systematically reviewed the PubMed and Scopus database up to October 2014 and also hand-searched the references of the retrieved articles for studies evaluating the effects of these agents on NAFLD. In animal studies, both GLP-1 receptor agonists and DPP-4 inhibitors reduced transaminase activity and steatosis but their effects on liver inflammation were inconsistent and fibrosis was not assessed. In clinical studies, both agents consistently reduced transaminase activity and steatosis as assessed non-invasively. There are very limited data on the effects of incretin-based treatments on liver histology. In conclusion, GLP-1 receptor agonists and DPP-4 inhibitors appear to hold promise in patients with NAFLD but larger controlled studies with histological and clinical endpoints are needed to evaluate their effects in this population.
Keywords: Glucagon-like peptide-1 analogues, dipeptidyl peptidase-4 inhibitors, non-alcoholic fatty liver disease, steatosis, type 2 diabetes mellitus.
Current Vascular Pharmacology
Title:Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Volume: 13 Issue: 5
Author(s): Theodora Nakouti, Apostolos K.A. Karagiannis, Konstantinos Tziomalos and Evangelos Cholongitas
Affiliation:
Keywords: Glucagon-like peptide-1 analogues, dipeptidyl peptidase-4 inhibitors, non-alcoholic fatty liver disease, steatosis, type 2 diabetes mellitus.
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and is more prevalent in patients with type 2 diabetes mellitus (T2DM). Incretin-based antidiabetic agents (glucagonlike peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors) are used in the treatment of T2DM but it is unclear whether they may also play a role in the management of NAFLD. We systematically reviewed the PubMed and Scopus database up to October 2014 and also hand-searched the references of the retrieved articles for studies evaluating the effects of these agents on NAFLD. In animal studies, both GLP-1 receptor agonists and DPP-4 inhibitors reduced transaminase activity and steatosis but their effects on liver inflammation were inconsistent and fibrosis was not assessed. In clinical studies, both agents consistently reduced transaminase activity and steatosis as assessed non-invasively. There are very limited data on the effects of incretin-based treatments on liver histology. In conclusion, GLP-1 receptor agonists and DPP-4 inhibitors appear to hold promise in patients with NAFLD but larger controlled studies with histological and clinical endpoints are needed to evaluate their effects in this population.
Export Options
About this article
Cite this article as:
Nakouti Theodora, Karagiannis K.A. Apostolos, Tziomalos Konstantinos and Cholongitas Evangelos, Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease, Current Vascular Pharmacology 2015; 13 (5) . https://dx.doi.org/10.2174/1570161112666141121112612
DOI https://dx.doi.org/10.2174/1570161112666141121112612 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Dysfunction, Oxidative Stress and Diabetic Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Assessment of Structural Compatibility of Saxagliptin in Physical Mixtures with some excipient by Using HPLC
Current Pharmaceutical Analysis Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Transmucosal Delivery of Metformin- A Comprehensive Study
Current Drug Delivery Patent Selections
Recent Patents on DNA & Gene Sequences Capillary Electrophoresis Interfaced with a Mass Spectrometer (CE-MS): Technical Considerations and Applicability for Biomarker Studies in Animals
Current Protein & Peptide Science Fibrates and Statins in the Treatment of Diabetic Retinopathy
Current Pharmaceutical Biotechnology Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome
Current Neurovascular Research Hypertensive Treatment and the Metabolic Syndrome
Current Hypertension Reviews Assessment of the Aggregation Propensity of the β -amyloid Peptide During the Synthesis and when Free in Solution
Protein & Peptide Letters Impaired Glycogen Synthase Activity and Mitochondrial Dysfunction in Skeletal Muscle: Markers or Mediators of Insulin Resistance in Type 2 Diabetes?
Current Diabetes Reviews Mitochondria Associated Membranes (MAMs): Emerging Drug Targets for Diabetes
Current Medicinal Chemistry Physiologic Versus Diabetogenic Effects of Interleukin-1: A Question of Weight
Current Pharmaceutical Design The Inhibitory Effect of Some Algerian Plants Phenolics Extracts on the α - glucosidase and α - amylase Activities and their Antioxidant Activities
Current Enzyme Inhibition Does Handle Region Peptide Provide Benefits in Chronic Kidney Disease?
Current Hypertension Reviews The Genetic Background of Cholesterol Gallstone Formation: An Inventory of Human Lithogenic Genes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design A Role for Insulin on L-Arginine Transport in Fetal Endothelial Dysfunction in Hyperglycaemia
Current Vascular Pharmacology